<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213316</url>
  </required_header>
  <id_info>
    <org_study_id>0518-145</org_study_id>
    <nct_id>NCT01213316</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)</brief_title>
  <acronym>WIP</acronym>
  <official_title>A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, non-comparative, multicenter, open-label study. Participants will
      be treated with Raltegravir according to standard clinical practice, and monitored over a
      total period of 96 weeks. In an extension to the study (Amendment 1), a new cohort of aging
      participants (≥ 50 years) will be recruited and monitored over a total period of 48 weeks.
      Participants who stop taking Raltegravir before the end of the 96-week period or 48-week
      period, respectively, will be followed up for 3 months after discontinuing the drug. The
      primary objective is to determine the proportion of participants with a human
      immunodeficiency virus (HIV)-1 viral load &lt; 50 copies/mL after 48 weeks of treatment with
      Raltegravir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Aging Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>The percentage of aging participants (&gt;=50 years old at initiation of raltegravir treatment) with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 96 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
    <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 96 weeks of raltegravir treatment was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load After 96 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
    <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined at Baseline and after 96 weeks of raltegravir treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ T-cell Counts After 96 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
    <description>Mean CD4+ T-cell counts were determined at baseline and after 96 weeks of raltegravir treatment. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Viral Load in Aging Participants After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ T-cell Counts in Aging Participants After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Mean CD4+ T-cell counts were determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at baseline and after 48 weeks of raltegravir treatment was determined. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Framingham Risk Score for the 10-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Mean Framingham Risk for 10-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment). Points were allotted for each of following 8 risk factors : sex, age, systolic blood pressure, treatment for hypertension, smoking, diabetes, total cholesterol, and high-density lipoprotein. The sum of the points for each participant was assigned a percent 10-year cardiovascular risk on a lookup table, and could range from 0% to 100%. The mean Framingham Risk for 10-year cardiovascular risk was then calculated for the analysis population. The change from baseline was calculated as Baseline minus Week 48; a positive change indicates reduced risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean D:A:D Risk Score for the 5-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Mean Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Score for 5-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment. The score included the following 8 risk factors: sex, age, systolic blood pressure, family cardiovascular disease history, current smoking, previous cigarette smoker, diabetes, total cholesterol, high-density lipoprotein, currently on indinavir, currently on lopinavir, currently on abacavir, duration and current use of indinavir and duration and current use of lopinavir. The D:A:D Risk Score is interpreted as low: &lt;1%; moderate: 1-5%; high: 5-10%; and very high: &gt;10%. The change from baseline was calculated as Week 48 minus Baseline; a positive change indicates increased risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Aging Participants With Concomitant Diseases at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The percentage of aging participants with Baseline comorbidities was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Aging Participants Taking Concomitant Medications at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The percentage of aging participants taking concomitant medication in addition to their other antiretroviral therapy was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">451</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Overall Participants</arm_group_label>
    <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aging Participants</arm_group_label>
    <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks</description>
    <arm_group_label>Aging Participants</arm_group_label>
    <other_name>ISENTRESS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks</description>
    <arm_group_label>Overall Participants</arm_group_label>
    <other_name>ISENTRESS®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with confirmed HIV-1 infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        The prospective participant must meet, at least, all of the criteria below to be eligible
        for study participation. The participant:

          -  Is a minimum age of 18 years (adults) or 50 years (aging participants);

          -  Is male or female;

          -  Has confirmed infection with HIV-1 (positive HIV test according to appropriate
             standard practice);

          -  Has commenced antiretroviral treatment with Raltegravir according to the
             recommendations made in the Summary of Product Characteristics at the time of
             enrollment on the study, or a maximum 6 months prior to enrollment on the study;

          -  Has any cluster of differentiation (CD4) cell (specialized white blood cell) count
             upon enrollment on the study.

        Exclusion criteria

        If the prospective participant meets any of the criteria below (among others determined by
        the study staff) they will NOT be eligible for study participation. The participant:

          -  For which Raltegravir, or its ingredients, are contraindicated;

          -  Has intolerance to Raltegravir, or its ingredients;

          -  If female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.</citation>
    <PMID>20543702</PMID>
  </reference>
  <reference>
    <citation>D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. Epub 2008 Jan 22.</citation>
    <PMID>18212285</PMID>
  </reference>
  <reference>
    <citation>Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293-8.</citation>
    <PMID>1985385</PMID>
  </reference>
  <reference>
    <citation>Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356-62.</citation>
    <PMID>1984895</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <results_first_submitted>March 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral</keyword>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Adults with HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Initial Cohort included participants &gt;=18 years old to receive treatment for 96 weeks. With the amendment, participants in the initial cohort &gt;=50 years old could continue for an additional 48-weeks observation (Prolonged Cohort), and participants &gt;=50 years old were newly enrolled to receive treatment for 48 weeks (Amendment Cohort).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Participants</title>
          <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="451">Participants in the initial and amendment cohorts</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Amendment Cohort: Prolonged Participants</title>
              <participants_list>
                <participants group_id="P1" count="48">Participants &gt;=50 years of age in the initial cohort who accept an additional 48-week observation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Amendment Cohort: Newly Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="179">Participants &gt;=50 years of age newly enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Treatment Before 48 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initial Cohort</title>
              <participants_list>
                <participants group_id="P1" count="272">Participants &gt;=18 years of age in the initial cohort</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Participants</title>
          <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</title>
        <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included all participants who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Participants</title>
            <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</title>
          <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
          <population>The analysis set included all participants who received at least one dose of raltegravir during the observation period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="46.1" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" lower_limit="70.4" upper_limit="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Aging Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</title>
        <description>The percentage of aging participants (&gt;=50 years old at initiation of raltegravir treatment) with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Aging Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 48 Weeks of Raltegravir Treatment</title>
          <description>The percentage of aging participants (&gt;=50 years old at initiation of raltegravir treatment) with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" lower_limit="55.5" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="71.5" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 96 Weeks of Raltegravir Treatment</title>
        <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 96 weeks of raltegravir treatment was determined.</description>
        <time_frame>Baseline and 96 weeks</time_frame>
        <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort Participants</title>
            <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks in combination with other antiretroviral drugs under conditions representative of standard clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an HIV-1 Viral Load &lt;50 Copies/mL After 96 Weeks of Raltegravir Treatment</title>
          <description>The percentage of participants with an HIV-1 viral load &lt;50 copies/mL of HIV-1 RNA after 96 weeks of raltegravir treatment was determined.</description>
          <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="37.8" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="62.1" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load After 96 Weeks of Raltegravir Treatment</title>
        <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined at Baseline and after 96 weeks of raltegravir treatment.</description>
        <time_frame>Baseline and 96 weeks</time_frame>
        <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort Participants</title>
            <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks in combination with other antiretroviral drugs under conditions representative of standard clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load After 96 Weeks of Raltegravir Treatment</title>
          <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined at Baseline and after 96 weeks of raltegravir treatment.</description>
          <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
          <units>Log10 Copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="1.65" lower_limit="62.1" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ T-cell Counts After 96 Weeks of Raltegravir Treatment</title>
        <description>Mean CD4+ T-cell counts were determined at baseline and after 96 weeks of raltegravir treatment. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
        <time_frame>Baseline and 96 weeks</time_frame>
        <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort Participants</title>
            <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks in combination with other antiretroviral drugs under conditions representative of standard clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ T-cell Counts After 96 Weeks of Raltegravir Treatment</title>
          <description>Mean CD4+ T-cell counts were determined at baseline and after 96 weeks of raltegravir treatment. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
          <population>The analysis set included participants in the Initial Cohort who received at least one dose of raltegravir during the observation period.</population>
          <units>CD4+ T-cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.9" spread="286.35" lower_limit="131.4" upper_limit="192.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 96 weeks: n=216</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.7" spread="225.98" lower_limit="131.4" upper_limit="192.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 Viral Load in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
        <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
          <description>The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
          <units>Log10 Copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="1.43" lower_limit="62.1" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ T-cell Counts in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
        <description>Mean CD4+ T-cell counts were determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at baseline and after 48 weeks of raltegravir treatment was determined. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ T-cell Counts in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
          <description>Mean CD4+ T-cell counts were determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at baseline and after 48 weeks of raltegravir treatment was determined. A positive change from baseline indicates an increase in CD4+ T-cell count.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
          <units>CD4+ T-cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534.4" spread="297.48" lower_limit="37.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 48 weeks: n=202</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="183.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Framingham Risk Score for the 10-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
        <description>Mean Framingham Risk for 10-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment). Points were allotted for each of following 8 risk factors : sex, age, systolic blood pressure, treatment for hypertension, smoking, diabetes, total cholesterol, and high-density lipoprotein. The sum of the points for each participant was assigned a percent 10-year cardiovascular risk on a lookup table, and could range from 0% to 100%. The mean Framingham Risk for 10-year cardiovascular risk was then calculated for the analysis population. The change from baseline was calculated as Baseline minus Week 48; a positive change indicates reduced risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period and had evaluable results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Framingham Risk Score for the 10-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
          <description>Mean Framingham Risk for 10-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment). Points were allotted for each of following 8 risk factors : sex, age, systolic blood pressure, treatment for hypertension, smoking, diabetes, total cholesterol, and high-density lipoprotein. The sum of the points for each participant was assigned a percent 10-year cardiovascular risk on a lookup table, and could range from 0% to 100%. The mean Framingham Risk for 10-year cardiovascular risk was then calculated for the analysis population. The change from baseline was calculated as Baseline minus Week 48; a positive change indicates reduced risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period and had evaluable results.</population>
          <units>Percentage risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="17.5" lower_limit="37.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 48 weeks: n=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean D:A:D Risk Score for the 5-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
        <description>Mean Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Score for 5-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment. The score included the following 8 risk factors: sex, age, systolic blood pressure, family cardiovascular disease history, current smoking, previous cigarette smoker, diabetes, total cholesterol, high-density lipoprotein, currently on indinavir, currently on lopinavir, currently on abacavir, duration and current use of indinavir and duration and current use of lopinavir. The D:A:D Risk Score is interpreted as low: &lt;1%; moderate: 1-5%; high: 5-10%; and very high: &gt;10%. The change from baseline was calculated as Week 48 minus Baseline; a positive change indicates increased risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period and had evaluable results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean D:A:D Risk Score for the 5-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment</title>
          <description>Mean Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Score for 5-year cardiovascular risk was determined in aging participants (&gt;=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment. The score included the following 8 risk factors: sex, age, systolic blood pressure, family cardiovascular disease history, current smoking, previous cigarette smoker, diabetes, total cholesterol, high-density lipoprotein, currently on indinavir, currently on lopinavir, currently on abacavir, duration and current use of indinavir and duration and current use of lopinavir. The D:A:D Risk Score is interpreted as low: &lt;1%; moderate: 1-5%; high: 5-10%; and very high: &gt;10%. The change from baseline was calculated as Week 48 minus Baseline; a positive change indicates increased risk. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period and had evaluable results.</population>
          <units>Percentage risk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.7" lower_limit="37.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 48 weeks: n=57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Aging Participants With Concomitant Diseases at Baseline</title>
        <description>The percentage of aging participants with Baseline comorbidities was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Aging Participants With Concomitant Diseases at Baseline</title>
          <description>The percentage of aging participants with Baseline comorbidities was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Aging Participants Taking Concomitant Medications at Baseline</title>
        <description>The percentage of aging participants taking concomitant medication in addition to their other antiretroviral therapy was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Aging Participants</title>
            <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Aging Participants Taking Concomitant Medications at Baseline</title>
          <description>The percentage of aging participants taking concomitant medication in addition to their other antiretroviral therapy was reported. This Outcome Measure was added with Amendment 1 and applies only to aging participants.</description>
          <population>The analysis set included aging participants (Prolonged Participants and Newly Enrolled Participants) who received at least one dose of raltegravir during the observation period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Participants: up to 48 weeks; Initial Cohort Participants: up to 96 weeks; Aging Participants: up to 48 weeks.</time_frame>
      <desc>Overall Participants and Aging Participants: MedDRA version 17.1; Initial Cohort Participants: MedDRA version 14.1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Participants</title>
          <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
        </group>
        <group group_id="E2">
          <title>Initial Cohort Participants</title>
          <description>HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
        </group>
        <group group_id="E3">
          <title>Aging Participants</title>
          <description>HIV-1 infected participants &gt;=50 years old received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1 and 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Spirochaetal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Q wave abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of this study will be published by the sponsor according to the current guidelines for publication. The Contract Research Organization will assist the sponsor with initial publication. Further details will be laid down in the financial agreement between the sponsor and the Contract Research Organization.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

